Clinical bottom line
Novel oral hypomethylating agents (HMAs) represent a promising therapeutic option for elderly patients with acute myeloid leukemia (AML) who are often ineligible for intensive chemotherapy due to comorbidities or frailty. These agents, either as monotherapy or in combination regimens, have demonstrated potential to improve response rates and survival with manageable toxicity profiles. However, evidence remains preliminary and largely derived from early-phase studies or retrospective analyses. Careful patient selection and further validation in randomized trials are needed before widespread adoption.
What the evidence shows
Hypomethylating agents such as azacitidine and decitabine have long been used intravenously or subcutaneously in elderly AML patients, but oral formulations are now emerging to improve convenience and adherence. Recent reviews highlight the development of oral HMAs, including oral azacitidine (CC-486), which has shown efficacy in maintenance therapy post-remission and in frontline settings for patients unfit for intensive therapy (Bhansali et al., 2023). These agents exert epigenetic modulation by inhibiting DNA methyltransferases, reactivating tumor suppressor genes, and promoting differentiation or apoptosis of leukemic blasts.
Combination therapies pairing oral HMAs with targeted agents such as venetoclax, a BCL-2 inhibitor, have gained attention. Venetoclax plus HMA regimens have demonstrated improved remission rates and overall survival compared to HMA monotherapy in elderly AML patients (Lachowiez et al., 2020; Sun et al., 2025). Oral HMAs facilitate outpatient administration and may enhance patient quality of life. For example, Tenneti et al. (2020) reported promising results using novel oral HMA combinations in elderly newly diagnosed AML, showing acceptable tolerability and encouraging response rates.
Tosedostat, an oral aminopeptidase inhibitor with hypomethylating activity, has also been investigated in relapsed/refractory AML, showing some activity but limited by toxicities and modest efficacy (DiNardo et al., 2014). Overall, oral HMAs appear to offer a feasible alternative to parenteral therapy, especially in frail or elderly populations.
Caveats and uncertainty
Despite encouraging early data, several uncertainties remain. Most evidence for oral HMAs comes from phase 1/2 trials, retrospective case reports, or small cohorts, limiting generalizability and statistical power (Tenneti et al., 2018; Huang et al., 2018). Long-term survival benefits and optimal dosing schedules require further elucidation. The heterogeneity of elderly AML patients, in terms of cytogenetics, comorbidities, and performance status, complicates treatment standardization.
Toxicity profiles, including myelosuppression and gastrointestinal adverse effects, require careful monitoring, especially in outpatient settings. Drug-drug interactions with oral agents also warrant consideration. Furthermore, the relative efficacy of oral HMAs compared to injectable formulations has not been definitively established in randomized controlled trials.
The impact of novel risk stratification models incorporating molecular and clinical parameters on treatment selection with oral HMAs is an evolving area (Sun et al., 2025). Finally, cost-effectiveness and patient preferences for oral versus parenteral therapy remain to be fully assessed.
How this may change practice
Oral hypomethylating agents have the potential to transform the management of elderly AML by enabling less intensive, more convenient treatment regimens that can be administered in outpatient or home settings. This may improve adherence, reduce hospital visits, and enhance quality of life, which are critical considerations in this vulnerable population.
Clinicians should remain informed about emerging data on oral HMAs and their combinations with agents like venetoclax to optimize individualized treatment plans. Incorporation of oral HMAs into treatment algorithms may expand therapeutic options for patients deemed unfit for intensive chemotherapy or stem cell transplantation.
However, given current evidence limitations, oral HMAs should be used within clinical trials or in carefully selected patients with close monitoring. Multidisciplinary collaboration and patient education are essential to manage expectations and adverse effects.
Ongoing and future randomized studies will clarify the role of oral HMAs in frontline and maintenance settings, potentially establishing new standards of care for elderly AML patients.